Morgan Stanley Longeveron Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$1.25 - $2.51 $875 - $1,756	700 New	700 $0
Q1 2023 May 15, 2023	SELL	$2.66 - $4.36 $10,424 - $17,086	-3,919 Reduced 84.85%	700 $1,000
Q4 2022 Feb 14, 2023	SELL	$2.81 - $39.7 $11,408 - $161,182	-4,060 Reduced 46.78%	4,619 $14,000
Q3 2022 Nov 14, 2022	BUY	$3.97 - $42.7 $29,294 - $315,083	7,379 Added 567.62%	8,679 $32,000
Q2 2022 Oct 27, 2022	SELL	$5.93 - $15.61 $296 - $780	-50 Reduced 3.7%	1,300 $8,000
Q2 2022 Aug 15, 2022	SELL	$5.93 - $15.61 $296 - $780	-50 Reduced 3.7%	1,300 $8,000
Q1 2022 Oct 27, 2022	BUY	$5.06 - $13.8 $252 - $690	50 Added 3.85%	1,350 $19,000
Q1 2022 May 13, 2022	BUY	$5.06 - $13.8 $2,023 - $5,520	400 Added 42.11%	1,350 $19,000
Q4 2021 Feb 14, 2022	BUY	$2.92 - $42.3 $2,190 - $31,724	750 Added 375.0%	950 $11,000
Q3 2021 Nov 15, 2021	BUY	$3.4 - $8.3 $680 - $1,660	200 New	200 $1,000

581

Ticker LGVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,925,940
Market Cap $12.4M
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.